How best to treat older patients with metastatic colorectal cancer?

Affiliations

¹ Georges Pompidou European Hospital, Department of Hepatogastroenterology and GI Oncology, Sorbonne Paris Cité/Université Paris Descartes, 75015 Paris, France. Electronic address: julien.taieb@aphp.fr.

Comment

Julien Taieb. Lancet Gastroenterol Hepatol. 2019 May.

. 2019 May;4(5):331-333.

doi: 10.1016/S2468-1253(19)30076-7. Epub 2019 Mar 7.

¹ Georges Pompidou European Hospital, Department of Hepatogastroenterology and GI Oncology, Sorbonne Paris Cité/Université Paris Descartes, 75015 Paris, France. Electronic address: julien.taieb@aphp.fr.

No abstract available

Comment on

Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.
Winther SB, Liposits G, Skuladottir H, Hofsli E, Shah CH, Poulsen LØ, Ryg J, Osterlund P, Berglund Å, Qvortrup C, Glimelius B, Sorbye H, Pfeiffer P. Winther SB, et al. Lancet Gastroenterol Hepatol. 2019 May;4(5):376-388. doi: 10.1016/S2468-1253(19)30041-X. Epub 2019 Mar 7. Lancet Gastroenterol Hepatol. 2019. PMID: 30852136 Clinical Trial.